Literature DB >> 16500782

Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis.

Sergio Sabbatani1, Roberto Manfredi, Ginevra Marinacci, Michele Pavoni, Lorenzo Cristoni, Francesco Chiodo.   

Abstract

The unexpected observation of severe pulmonary tuberculosis after a 7-month combined pegylated interferon-ribavirin for chronic hepatitis C, prompted us to search an eventual immunodeficiency (lymphopenia and/or depletion of CD4+ T-lymphocytes. The retrieval of a chest radiograph incidentally performed 11 y before and showing a probable primary tuberculosis, paralleled a negligible clinical history. The enlargement of interferon indications needs careful evaluation for prior (usually missed) tuberculosis, to prevent or avoid its possible reactivation. Latent tuberculosis is increasingly reported because of extended life expectancy, immigration, and recent availability of cure for multiple chronic disorders, which are often borne by primary-secondary immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16500782     DOI: 10.1080/00365540500263268

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  14 in total

1.  Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.

Authors:  Michael T Melia; Norbert Bräu; Fred Poordad; Eric J Lawitz; Mitchell L Shiffman; John G McHutchison; Andrew J Muir; Greg W Galler; Lisa M Nyberg; William M Lee; Eugene Schiff; Jianmin Long; Stephanie Noviello; Clifford A Brass; Lisa D Pedicone; Mark S Sulkowski
Journal:  Clin Infect Dis       Date:  2014-01-06       Impact factor: 9.079

2.  Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1β production in human macrophages.

Authors:  Aleksey Novikov; Marco Cardone; Robert Thompson; Kevin Shenderov; Kevin D Kirschman; Katrin D Mayer-Barber; Timothy G Myers; Ronald L Rabin; Giorgio Trinchieri; Alan Sher; Carl G Feng
Journal:  J Immunol       Date:  2011-07-22       Impact factor: 5.422

3.  Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection.

Authors:  Alejandra N Martinez; Smriti Mehra; Deepak Kaushal
Journal:  J Infect Dis       Date:  2013-01-28       Impact factor: 5.226

Review 4.  Antitubercular therapy in patients with cirrhosis: challenges and options.

Authors:  Naveen Kumar; Chandan Kumar Kedarisetty; Sachin Kumar; Vikas Khillan; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

5.  Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response.

Authors:  Karen Cilliers; Angela Menezes; Tariq Webber; Hazel M Dockrell; Jacqueline M Cliff; Léanie Kleynhans; Novel N Chegou; Nelita du Plessis; André G Loxton; Martin Kidd; Joel Fleury Djoba Siawaya; Katharina Ronacher; Gerhard Walzl
Journal:  Tuberculosis (Edinb)       Date:  2021-04-10       Impact factor: 3.131

6.  Tuberculosis screening before anti-hepatitis C virus therapy in prisons.

Authors:  Sergio Babudieri; Andrea Soddu; Monica Murino; Paola Molicotti; Alberto A Muredda; Giordano Madeddu; Alessandro G Fois; Stefania Zanetti; Pietro Pirina; Maria Stella Mura
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883

7.  Tuberculous peritonitis after treatment for chronic hepatitis C.

Authors:  Evangelos Cholongitas; Theodora Nakouti; Evangelos Akriviadis
Journal:  Ann Gastroenterol       Date:  2014

8.  Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.

Authors:  Shang-Yi Lin; Tun-Chieh Chen; Po-Liang Lu; Chun-Yu Lin; Wei-Ru Lin; Yi-Hsin Yang; Yen-Hsu Chen
Journal:  BMC Infect Dis       Date:  2014-12-19       Impact factor: 3.090

Review 9.  Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences.

Authors:  Meg L Donovan; Thomas E Schultz; Taylor J Duke; Antje Blumenthal
Journal:  Front Immunol       Date:  2017-11-27       Impact factor: 7.561

Review 10.  Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.

Authors:  Bas C Mourik; Erik Lubberts; Jurriaan E M de Steenwinkel; Tom H M Ottenhoff; Pieter J M Leenen
Journal:  Front Immunol       Date:  2017-04-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.